MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
Summary
The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM). The treatment on this study will consist of Induction chemotherapy and stem cell collection, Immunotherapy 1 chemotherapy and Immunotherapy 2 chemotherapy. For participants whose testing show they are Minimal Residual Disease (MRD) positive (still have myeloma cells present in the bone marrow testing), a Melphalan-based stem cell transplant will be performed. For participants whose testing show they are MRD negative, the stem cell transplant will not be performed. All participants will go on to receive Immunotherapy 3 chemotherapy, Immunotherapy 4 chemotherapy, and Maintenance therapy.
Timeline
- Start
- 2027-03-01
- Primary completion
- 2030-04-01
- Completion
- 2032-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | — |
| Subject | Lenalidomide | Other / unclassified | — | — |
| Subject | Melphalan | Small molecule | — | — |
| Subject | Talquetamab | Monoclonal antibody | — | — |
| Subject | Teclistamab | Monoclonal antibody | — | — |